Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ellen G. Press"'
Autor:
Samuel A. Shelburne, Xiqi Li, Cesar A. Arias, Ellen G. Press, Min S. Kim, Jiwoong Kim, Samuel L. Aitken, Ying Jiang, Jose M. Munita, Ryan K. Shields, Brandi L. Cantarel, Pranoti Sahasrabhojane, David E. Greenberg
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Background There is marked interest in using DNA-based methods to detect antimicrobial resistance (AMR), with targeted polymerase chain reaction (PCR) approaches increasingly being incorporated into clinical care. Whole-genome sequencing (WGS) could
Autor:
M. Hong Nguyen, Ghady Haidar, Brian A. Potoski, Barry N. Kreiswirth, Liang Chen, Binghua Hao, Yohei Doi, Cornelius J. Clancy, Ryan K. Shields, Ellen G. Press
Publikováno v:
Clinical Infectious Diseases. 63:1615-1618
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes,
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:3187-3192
Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharm
Autor:
M. Hong Nguyen, Cornelius J. Clancy, Eileen Driscoll, Ellen G. Press, Ryan K. Shields, A. William Pasculle, Richard Cumbie
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:7465-7470
Precise FKS mutation rates among Candida species are undefined because studies have not systematically screened consecutive, disease-causing isolates. The Sensititre YeastOne (SYO) assay measures echinocandin MICs against Candida with less variabilit
Autor:
Cornelius J. Clancy, M. Hong Nguyen, Liang Chen, Ellen G. Press, Barry N. Kreiswirth, Ryan K. Shields
Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant Enterobacteriaceae (CRE) infections at our center. Thirty- and 90-day survival rates were 81% and 69%, respectively; these rates were higher than those predicted by SAPS II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c29cd0917ff50b76e04facd1ba15ab0
https://europepmc.org/articles/PMC5923134/
https://europepmc.org/articles/PMC5923134/
Autor:
Derek N. Bremmer, Ryan K. Shields, M. Hong Nguyen, Ellen G. Press, Reem Almaghrabi, Yohei Doi, Cornelius J. Clancy, Liang Chen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:7597-7600
The aminoglycoside-modifying enzyme AAC(6′)-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6′)-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. B
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:7601-7605
FKS mutant Candida isolates were recovered from 24% (6/25) of abdominal candidiasis patients exposed to echinocandin. Candida glabrata (29%) and Candida albicans (14%) mutants were identified. Multidrug-resistant bacteria were recovered from 83% of F
Autor:
Cornelius J. Clancy, Yohei Doi, Brian A. Potoski, M. Hong Nguyen, Barry N. Kreiswirth, Liang Chen, Ellen G. Press, Ryan K. Shields, Rachel V Marini
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumonia
Autor:
Ghady Haidar, Binghua Hao, Barry N. Kreiswirth, Liang Chen, Ryan K. Shields, M. Hong Nguyen, A. William Pasculle, Cornelius J. Clancy, Ellen G. Press
Publikováno v:
Journal of clinical microbiology. 56(2)
Ceftazidime-avibactam and ceftolozane-tazobactam are newly approved agents for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Resistance to both agents has been described clinically. Susceptibility testing on automa
Autor:
M. Hong Nguyen, Ryan K. Shields, Ellen G. Press, Cornelius J. Clancy, Barry N. Kreiswirth, Liang Chen
Publikováno v:
Open Forum Infectious Diseases
We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible Klebsiella pneumoniae that carried mutant blaKPC-3. Meropenem was bactericidal against ceftazidime-avibactam- resistant K